Molecular mechanisms of Huanglian Jiedu decoction in treating Alzheimer’s disease by regulating microbiome via network pharmacology and molecular docking analysis

Renyuan Zheng, Shenggan Shi, Qin Zhang, Shuqin Yuan, Tong Guo, Jinlin Guo, Peidu JiangFrontiers in Cellular and Infection Microbiology 2023 · DOI

TL;DR

This study employs network pharmacology and molecular docking to decode the complex "multi-component, multi-target" mechanism of Huanglian Jiedu decoction (HLJDD), a traditional Chinese medicine, in treating Alzheimer’s Disease (AD). The researchers identified 102 bioactive compounds and 76 key targets, suggesting that HLJDD exerts its therapeutic effects by modulating neuroinflammation and the microbiome-gut-brain axis.

What Problem Does This Paper Address?

Alzheimer’s Disease (AD) remains one of the most challenging neurodegenerative conditions, with current FDA-approved drugs largely limited to symptomatic relief rather than reversing the disease. The "one drug, one target" paradigm has struggled against AD's complex pathology.

Traditional Chinese Medicine (TCM), specifically Huanglian Jiedu decoction (HLJDD), has shown clinical promise in treating AD, but its underlying molecular mechanisms remain a "black box." Furthermore, emerging research suggests the microbiome-gut-brain axis plays a critical role in AD progression. This paper seeks to bridge the gap between ancient herbal wisdom and modern systems biology by mapping how HLJDD’s chemical constituents interact with human biological pathways and the microbial environment.

Methods

The authors utilized a multi-stage computational pipeline:

  1. Network Pharmacology: They screened the chemical constituents of the four herbs in HLJDD (Rhizoma coptidis, Radix scutellariae, Cortex phellodendri, and Fructus gardeniae) using the TCMSP database, filtering for high oral bioavailability (OB) and drug-likeness (DL).
  2. Target Prediction: Potential protein targets for these compounds were identified and cross-referenced with known AD-related genes from databases like GeneCards and OMIM.
  3. Bioinformatics Analysis:
    • Protein-Protein Interaction (PPI): Constructed using STRING and Cytoscape to find "hub" proteins.
  4. Enrichment Analysis: GO (Gene Ontology) and KEGG (Kyoto Encyclopedia of Genes and Genomes) analyses were performed via the DAVID platform to identify which biological processes and signaling pathways were most affected.
  5. Molecular Docking: To validate the computational predictions, the authors simulated the physical binding of the top 8 bioactive compounds to the top 8 hub proteins using AutoDock Vina and PyMOL.

Datasets

The study relied on several established biological and pharmacological databases:

  • TCMSP: For TCM components and pharmacokinetic properties.
  • GeneCards, OMIM, and TTD: For identifying human genes associated with Alzheimer’s Disease.
  • UniProt: For protein sequence and functional information standardization.
  • PDB (Protein Data Bank): For obtaining 3D structures of target proteins used in docking simulations.
  • STRING: For mapping protein-protein interaction networks.

Key Insights and Ideas

  • The "Cocktail" Effect: Rather than a single active ingredient, HLJDD works through a synergistic group of compounds—primarily flavonoids (like kaempferol, wogonin, and baicalein) and sterols (beta-sitosterol).
  • Central Hubs of Inflammation: The analysis highlighted AKT1, TNF, and TP53 as core targets. This suggests that HLJDD’s primary mode of action is the regulation of cell survival and the suppression of neuroinflammation.
  • Microbiome-Gut-Brain Axis: The authors hypothesize that HLJDD regulates the homeostasis of microbial flora. By targeting pathways like NF-κB and VEGF, the decoction may reduce the systemic inflammation triggered by gut dysbiosis, which is known to exacerbate amyloid-beta (Aβ) accumulation in the brain.
  • Pathway Convergence: The study found that HLJDD targets converge on the VEGF signaling pathway, which is crucial for vascular health and neuroprotection, and the calcium signaling pathway, which is often disrupted in AD neurons.

Key Results

  • Screening Success: 102 bioactive ingredients were identified from HLJDD, interacting with 76 targets specifically related to AD.
  • Strong Binding Affinities: In the molecular docking validation, all top 8 compounds showed binding energies lower than -5.0 kcal/mol with their respective targets, indicating high stability and strong potential for biological activity.
  • Top Compounds: Kaempferol and wogonin emerged as the most "connected" ingredients, showing high degrees of interaction across the target network.
  • Pathway Enrichment: 15 significant signaling pathways were identified, with "Pathways in cancer" (often sharing cell-cycle and apoptotic machinery with neurodegeneration) and "NF-kappa B signaling" being among the most prominent.

Limitations and Future Work

The primary limitation of this study is that it is entirely in silico (computational). While network pharmacology and molecular docking provide a sophisticated roadmap, they cannot fully account for the complex metabolic transformations that occur in the human body (pharmacokinetics) or the actual changes in microbial populations.

Future Work suggested by the authors includes:

  • In vivo validation: Testing these specific compounds in AD animal models to measure actual changes in gut microbiota and neuroinflammatory markers.
  • Clinical Correlation: Investigating whether the identified "hub" proteins (like AKT1 or TNF) actually shift in patients treated with HLJDD.
  • Microbiome Sequencing: Direct 16S rRNA sequencing of gut flora in treated subjects to confirm the "microbiome regulation" hypothesis.

Summary updated

Abstract

Our results comprehensively illustrated the bioactives, potential targets, and possible molecular mechanisms of HLJDD against AD. HLJDD may regulate the microbiota flora homeostasis to treat AD through multiple targets and multiple pathways. It also provided a promising strategy for the use of traditional Chinese medicine in treating human diseases.
BibTeX
@inproceedings{zheng2023molecular,
  author = {Renyuan Zheng and Shenggan Shi and Qin Zhang and Shuqin Yuan and Tong Guo and Jinlin Guo and Peidu Jiang},
  title = {{Molecular mechanisms of Huanglian Jiedu decoction in treating Alzheimer’s disease by regulating microbiome via network pharmacology and molecular docking analysis}},
  booktitle = {Frontiers in Cellular and Infection Microbiology},
  year = {2023},
  doi = {10.3389/fcimb.2023.1140945},
}
Figure